Injectable Buprenorphine in Prison: a Preference Trial

Launched by LIFESPAN · Mar 14, 2025

Keywords

ClinConnect Summary

This clinical trial, called "Injectable Buprenorphine in Prison: a Preference Trial," is studying two types of long-acting buprenorphine medications, Sublocade and Brixadi, to see which one helps people with opioid use disorder (OUD) stay in treatment after they are released from prison. The trial will help researchers understand if allowing individuals to choose their preferred medication makes a difference in how well they do in their recovery. Participants will either pick their medication or be assigned one randomly, and they will receive monthly injections of either medication for six months after their release. Throughout the trial, they will complete surveys and assessments about their treatment experience.

To be eligible for the trial, participants must be at least 18 years old, currently incarcerated, diagnosed with OUD, and expected to be released within 120 days. Those who are pregnant, have certain medical or psychiatric conditions, or have had an allergy to buprenorphine cannot participate. This study is important because it aims to improve treatment outcomes for individuals transitioning back into the community after incarceration, helping them lead safer and healthier lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. be at least 18 years of age and incarcerated in the RIDOC facility,
• • 2. be currently diagnosed with OUD and enrolled in the RIDOC MOUD program,
• • 3. have an expected release date within 120 days of study enrollment,
• • 4. have an interest in XR-B and
• • 5. be English speaking
• Exclusion Criteria:
• • 1. individuals who are pregnant or planning conception,
• • 2. diagnosed with a severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely,
• • 3. have a release date within 21 days of initiation, or
• • 4. have previously had an allergy to buprenorphine. Post-enrollment exclusion will include individuals if there is a change in release date beyond the 120 days and therefore no longer meet original inclusion criteria. These individuals would return to usual MOUD care.